Many individuals have been told that their illness is "treatment resistant." However, this only means that they haven't ...

Bristol Myers Squibb’s Cobenfy is the first treatment in seven decades that does not modulate dopaminergic or serotonergic ...

The schizophrenia market across the seven major markets is poised to grow at a compound annual growth rate (CAGR) of 7.4% ...

An estimated one-quarter to one-third of people with schizophrenia have symptoms that don’t improve with traditional ...

In the wake of the approval Bristol Myers Squibb’s Cobenfy, it seems that news has ramped up in the schizophrenia space. | In ...

Gut microbiome treatment-resistant schizophrenia - Nuala Murray explores the role of the gut microbiome in ...

In a comprehensive Genomic Press Interview, distinguished psychiatrist Professor Peter Falkai suggests promising new ...

Newron Pharmaceuticals has secured 44 million euros ($46.1 million) in upfront cash from an Eisai subsidiary for select Asia ...

Imagine a breakthrough that could help millions suffering from schizophrenia — a condition that dampens emotional expression ...

Shares of Bristol-Myers Squibb Co. rose by about 1% on Monday afternoon following an upgrade from Jefferies. The brokerage ...

According to GlobalData’s Drugs Database, the schizophrenia market remains dominated by dopamine-targeted mechanisms, such as ...